TAF vs TDF to prevent passing hepatitis B to babies
Part of Digestive system, Infections clinical trials.
This trial tests if TAF is safer and as effective as TDF for pregnant women with high hepatitis B viral loads to prevent passing the virus to their babies. You may qualify if you are pregnant, between 20-28 weeks, and have high viral levels.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are pregnant and between 20 and 40 years old
- You are between 20 and 28 weeks pregnant
- You have had hepatitis B for more than 6 months and still have the virus active in your blood
- Your hepatitis B viral load is very high (over 200,000 IU/mL)
- You and your baby's father agree to participate and understand the risks
- You agree to avoid pregnancy for 28 weeks after giving birth
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental antibody treatment for people with chronic hepatitis B who have been on antiviral medication for at least 6 months. It aims to see if the antibody is safe and can help control the virus.
This trial tests if taking tenofovir alafenamide (TAF) alone works as well as combining it with entecavir (ETV) to improve outcomes for people with hepatitis B and liver cancer who are receiving immunotherapy.
This Phase 1 trial tests HepB mAb19, an antibody medicine, in adults with chronic hepatitis B. The goal is to see how it works and how safe it is in people whose hepatitis B is controlled on current antiviral treatment.
This trial tests a hepatitis B medicine called TAF in pregnant women who need antiviral treatment. It helps protect both mom and baby from complications of the virus.
This study compares two antiviral medications (TAF and TDF) in pregnant women with hepatitis B to see which is safer and more effective during pregnancy and for the baby's health.
This study tests tenofovir alafenamide (TAF) to lower hepatitis B in pregnant people and reduce the chance of passing it to the baby. You may be able to join if you’re pregnant with active hepatitis B and meet safety lab and pregnancy ultrasound requirements.
Hear when a new Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.